Core Viewpoint - The company has approved an associated transaction with China Guoxin, involving a contract worth RMB 2,840,000 for the development of a legal compliance system for equity investment [2][6][21]. Group 1: Meeting and Decision - The 7th meeting of the 12th Board of Directors was held on November 10, 2025, with all 9 directors present, and the meeting complied with legal and regulatory requirements [1][4]. - The proposal regarding the associated transaction with China Guoxin was approved with 5 votes in favor, 0 against, and 0 abstentions, with certain directors abstaining from voting due to conflicts of interest [2][8]. Group 2: Transaction Details - The contract involves the development of the "China Guoxin Equity Investment Legal Compliance Intelligent Review System" by the company's wholly-owned subsidiary, Guoxin Health Service Co., Ltd. [5][17]. - The total contract amount is RMB 2,840,000, which will be paid in installments based on project milestones and acceptance [18][21]. Group 3: Related Party Information - China Guoxin is the actual controller of the company and is classified as a related party under relevant regulations [7][15]. - The cumulative amount of transactions with China Guoxin over the past twelve months has reached RMB 4.434 million, meeting the disclosure standards for board review [23]. Group 4: Independent Directors' Opinion - The independent directors unanimously agreed that the associated transaction aligns with the company's operational needs, is reasonably priced, and does not significantly impact the company's independence or harm the interests of minority shareholders [21][22].

Core Points - Guoxin Health announced the approval of a related party transaction with China Guoxin, involving the construction of a legal compliance intelligent review system for equity investment [2] - The contract amount for the project is RMB 2,840,000, which includes tax [2] - The transaction is classified as a related party transaction since China Guoxin is the actual controller of the company [2]

格隆汇11月10日丨国新健康(000503.SZ)公布，公司全资子公司国新健康保障服务有限公司（简称"国新 健康有限"）与中国国新控股有限责任公司（简称"中国国新"）拟签署《中国国新股权投资法律合规智 能审查系统建设服务合同》，由国新健康有限为中国国新建设"中国国新股权投资法律合规智能审查系 统"，负责完成应用软件的设计开发、移交、培训及相关其他服务工作，合同金额（含税价）为人民币 2,840,000元。 ...

Core Viewpoint - Guoxin Health (000503.SZ) announced a contract with China Guoxin Holdings to develop a legal compliance intelligent review system for equity investments, valued at RMB 2,840,000 [1] Group 1 - Guoxin Health's wholly-owned subsidiary, Guoxin Health Guarantee Service Co., Ltd., will undertake the project [1] - The contract includes responsibilities for application software design, development, handover, training, and related services [1] - The total contract amount is RMB 2,840,000, including tax [1]